Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 14/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6852054 | 0.82 | TSHR (0.39) | TSHRCRHR1SLC2A1 | |
| SCHEMBL5054212 | 0.77 | TSHR (0.41) | TSHRCRHR1 | |
| SCHEMBL2072250 | 0.66 | ELANE (0.33) | TSHRCRHR1SLC2A1 | |
| SCHEMBL5567895 | 0.63 | CRHR1 (0.38) | TSHRCRHR1SLC2A1 | |
| SCHEMBL5061545 | 0.62 | CRHR1 (0.37) | TSHRCRHR1 | |
| SCHEMBL704340 | 0.62 | SLC6A2 (0.59) | SLC2A1 | |
| SCHEMBL29412428 | 0.62 | SLC6A2 (0.59) | SLC2A1 | |
| SCHEMBL31555764 | 0.61 | KDM4E (0.33) | — | |
| SCHEMBL7029606 | 0.61 | TSHR (0.33) | TSHRCRHR1 | |
| SCHEMBL5054139 | 0.61 | CRHR1 (0.38) | TSHRCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-05-06 | — | — | US | disclosed |
| US-6531475-B1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2001087885-A1 | CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | TSHR 180/4885CRHR1 1/4885SLC2A1 609/4885 |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | TSHR 180/4885CRHR1 1/4885SLC2A1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.